KOD · Nasdaq · CIK 0001468748
Kodiak Sciences Inc.
Kodiak Sciences Inc.’s most recent SEC filing in our snapshot is a Form 4 filed on Oct 26, 2026. Its EDGAR record lists 20 Form 4 insider filings from the 12 months before our last refresh.
SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.
Company overview
- Legal name (as filed)
- Kodiak Sciences Inc.
- Ticker
- KOD
- SEC Central Index Key (CIK)
- 0001468748
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (code 2836)
- Business address
- PALO ALTO, CA
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- SEC filer category
- Non-accelerated filer<br>Smaller reporting company
- Position in SEC ticker list
- #1288 of the 3,000 companies we track
Five-year financial highlights
Full-year figures from Kodiak Sciences Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.
| Item | FY2021 ended Dec 31, 2021 | FY2022 ended Dec 31, 2022 | FY2023 ended Dec 31, 2023 | FY2024 ended Dec 31, 2024 | FY2025 ended Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net income | -$267.0M | -$333.8M | -$260.5M | -$176.2M | -$230.0M |
| Diluted EPS | -$5.16 | -$6.39 | -$4.97 | -$3.35 | -$4.32 |
| Total assets | $904.2M | $666.6M | $479.4M | $335.6M | $351.5M |
| Cash and equivalents | $731.5M | $190.4M | $285.5M | $168.1M | $209.9M |
XBRL tags used: netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.
How to read these numbers
Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.
Advertisement
Latest key reports
The most recent filing of each major report type, even if it falls outside the 40 newest filings below.
| Filed | Form | What it is | Original |
|---|---|---|---|
| Mar 31, 2026 | 10-K | Annual report· period Dec 31, 2025 | Document · Index |
| Aug 13, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Sep 28, 2026 | 8-K | Other events· period Sep 28, 2026 | Document · Index |
| Apr 22, 2026 | DEF 14A | Definitive proxy statement· period Jun 2, 2026 | Document · Index |
Recent SEC filings
The 40 newest documents filed by or about Kodiak Sciences Inc., by form type:
| Filed | Form | What it is | Original |
|---|---|---|---|
| Oct 26, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 23, 2026 | Document · Index |
| Oct 23, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Oct 21, 2026 | Document · Index |
| Oct 21, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Oct 20, 2026 | S-3ASR | Simplified registration statement | Document · Index |
| Sep 30, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 28, 2026 | Document · Index |
| Sep 30, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 28, 2026 | Document · Index |
| Sep 30, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 28, 2026 | Document · Index |
| Sep 30, 2026 | SCHEDULE 13D/A | Active beneficial ownership report (over 5%) | Document · Index |
| Sep 29, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 25, 2026 | Document · Index |
| Sep 28, 2026 | 8-K | Other events· period Sep 28, 2026 | Document · Index |
| Aug 14, 2026 | SCHEDULE 13G | Passive beneficial ownership report (over 5%) | Document · Index |
| Aug 13, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Aug 13, 2026 | 8-K | Results of operations· period Aug 13, 2026 | Document · Index |
| Jul 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jul 15, 2026 | Document · Index |
| Jul 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jul 15, 2026 | Document · Index |
| Jul 2, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 30, 2026 | Document · Index |
| Jul 2, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 30, 2026 | Document · Index |
| Jul 2, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 30, 2026 | Document · Index |
| Jul 2, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 30, 2026 | Document · Index |
| Jul 2, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 30, 2026 | Document · Index |
| Jul 2, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 30, 2026 | Document · Index |
| Jun 5, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026 | Document · Index |
| Jun 4, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Jun 4, 2026 | 8-K | Shareholder vote results· period Jun 2, 2026 | Document · Index |
| May 15, 2026 | SCHEDULE 13G | Passive beneficial ownership report (over 5%) | Document · Index |
| May 7, 2026 | 10-Q | Quarterly report· period Mar 31, 2026 | Document · Index |
| May 7, 2026 | 8-K | Results of operations· period May 7, 2026 | Document · Index |
| Apr 27, 2026 | SCHEDULE 13G | Passive beneficial ownership report (over 5%) | Document · Index |
| Apr 23, 2026 | ARS | ARS· period Dec 31, 2025 | Document · Index |
| Apr 22, 2026 | DEFA14A | Additional proxy soliciting materials | Document · Index |
| Apr 22, 2026 | DEF 14A | Definitive proxy statement· period Jun 2, 2026 | Document · Index |
| Apr 16, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Apr 15, 2026 | Document · Index |
| Apr 2, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Apr 2, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Apr 2, 2026 | Document · Index |
| Apr 2, 2026 | SCHEDULE 13G | Passive beneficial ownership report (over 5%) | Document · Index |
| Mar 31, 2026 | S-8 | Registration of employee benefit plan securities | Document · Index |
| Mar 31, 2026 | 10-K | Annual report· period Dec 31, 2025 | Document · Index |
| Mar 31, 2026 | 8-K | Results of operations· period Mar 31, 2026 | Document · Index |
| Mar 27, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 25, 2026 | Document · Index |
| Mar 27, 2026 | 8-K | Other events· period Mar 26, 2026 | Document · Index |
Insider filing activity
20 Form 4 filings appear in Kodiak Sciences Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.
Advertisement
Other companies in Biological Products, (No Diagnostic Substances)
- AMGN AMGEN INC
- GILD GILEAD SCIENCES, INC.
- MRNA Moderna, Inc.
- ARGX ARGENX SE
- RVMD Revolution Medicines, Inc.
- BIIB BIOGEN INC.
- BNTX BioNTech SE
- EXEL EXELIXIS, INC.
All 61 companies in Biological Products, (No Diagnostic Substances)· Companies headquartered in California
On Amazon
Popular tools for investors
As an Amazon Associate I earn from qualifying purchases.
Source
- U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001468748 and XBRL company facts. Kodiak Sciences Inc. on EDGAR.
- Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.
Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.
Advertisement